- Home
- SAIA vs ABVX Comparison
SAIA vs ABVX Comparison
Compare SAIA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAIA | ABVX |
|---|---|---|
| Founded | 1924 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.5B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | SAIA | ABVX |
|---|---|---|
| Price | $366.96 | $109.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | ★ $382.44 | $128.42 |
| AVG Volume (30 Days) | 546.1K | ★ 733.0K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.52 | N/A |
| Revenue | ★ $3,234,286,000.00 | N/A |
| Revenue This Year | $6.33 | N/A |
| Revenue Next Year | $9.33 | $0.22 |
| P/E Ratio | $37.45 | ★ N/A |
| Revenue Growth | ★ 0.79 | N/A |
| 52 Week Low | $248.37 | $4.77 |
| 52 Week High | $430.11 | $148.83 |
Technical Indicators
Market Signals| Indicator | SAIA | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 38.60 |
| Support Level | $327.81 | $107.99 |
| Resistance Level | $415.11 | $131.27 |
| Average True Range (ATR) | 21.09 | 4.98 |
| MACD | -5.31 | -1.76 |
| Stochastic Oscillator | 30.11 | 14.69 |
Price Performance
Historical ComparisonAbout SAIA Saia Inc.
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.